VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea

Background: Overall, there are over 30 different sexually transmitted infections with Neisseria gonorrhoeae being the third most frequent a reported 78 million cases per year. Gonococcal infection causes genital inflammation, which can be risk factor for others infections, particularly human immunodeficiency virus. Gonorrhea is treatable disease, but recently an increase in antibiotic resistance has been of concern. There currently no vaccines available. However, parenteral vaccination anti N. meningitidis serogroup B vaccine to decrease incidence gonococcal burden New Zealand and Cuba despite fact that not deemed induce mucosal IgA. Here we explore possible mechanisms protection against through meningococcal vaccination. Methods: Ninety-two serum, saliva oropharyngeal swabs samples young adults (healthy carriers) internal higher school were obtained. They have vaccinated VA-MENGOC-BC (MBV) during their infancy boosted dose this study. Serum analyzed by ELISA Western blot measured IgG IgA antibodies antigens. carriers determined standard microbiologic test. In addition, reviewed epidemiologic data Cuba. Results: Epidemiologic show influence MBV gonorrhea suggesting dependent sexual arrival age syphilis. Laboratorial permit detection 70 22 noncarriers meningitidis, respectively. anti-MBV antigens (PL) responses independent carriage stages, anti-PL only present significant induced subjects. Carriers similar antigonococcal -PL serum responses; meanwhile, was significantly lower. saliva, at least 2 identified blot. Finally, gonococcal-specific antibody responses, addition antibodies, might contributed reduction gonorrhoeae. We hypothesize observed reductions Conclusion: These results suggest mechanism Proteoliposome-based BC on incidence.